Mark Dolman

Title: Mark Dolman: Innovator in Pharmaceutical Formulations

Introduction

Mark Dolman is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical formulations, particularly through his innovative patents. With a total of two patents to his name, Dolman is recognized for his work in developing boronic acid salts and their applications in drug formulations.

Latest Patents

Dolman's latest patents include "Boronic acid salts useful in parenteral formulations" and "Multivalent metal salts of boronic acids." The first patent focuses on salts of a peptide boronic acid drug, such as Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH). The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound. The second patent addresses salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug, with examples including calcium, magnesium, and zinc. These organoboronic acid drugs may serve as boropeptide protease inhibitors and can be formulated in oral dosage forms.

Career Highlights

Mark Dolman is currently associated with Trigen GmbH, where he continues to advance his research and development efforts in the pharmaceutical sector. His work has garnered attention for its potential impact on drug delivery systems and therapeutic applications.

Collaborations

Dolman collaborates with esteemed colleagues, including John Joseph Deadman and Sanjay Kumar Kakkar, who contribute to his innovative projects and research initiatives.

Conclusion

Mark Dolman's contributions to pharmaceutical formulations through his patents highlight his role as a key innovator in the field. His work continues to pave the way for advancements in drug delivery and therapeutic solutions.